A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD9977 in Participants With Renal Impairment
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Balcinrenone (Primary)
- Indications Cardiovascular disorders; Heart failure; Kidney disorders
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Mar 2022 Status changed from recruiting to completed.
- 14 Jul 2021 Planned End Date changed from 16 Aug 2021 to 15 Dec 2021.
- 14 Jul 2021 Planned primary completion date changed from 16 Aug 2021 to 15 Dec 2021.